Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study

Gabriella Iannuzzo, Alessio Buonaiuto,Ilenia Calcaterra, Marco Gentile,Francesco Forte, Maria Tripaldella,Maria D. Di Taranto, Carola Giacobbe,Giuliana Fortunato, Paolo O. Rubba,Matteo N. Dario Di Minno

Nutrition, Metabolism and Cardiovascular Diseases（2022）

引用 7|浏览11

暂无评分

摘要

•After 36 weeks there were no differences in response to PCSK9-I therapy between FH subgroups according to genotype.•Response to PCSK9-I was significantly lower in carriers of compound-He/Ho mutations.•Target achievement rate still represents an issue in FH patients despite high efficacy of available lipid lowering therapy.

查看译文

关键词

Familial hypercholesterolemia,Proprotein convertase subtilisin/kexin type 9 inhibitors,Low-density lipoprotein cholesterol,Low-density lipoprotein receptor gene

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要